Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11761085rdf:typepubmed:Citationlld:pubmed
pubmed-article:11761085lifeskim:mentionsumls-concept:C0007012lld:lifeskim
pubmed-article:11761085lifeskim:mentionsumls-concept:C0728940lld:lifeskim
pubmed-article:11761085lifeskim:mentionsumls-concept:C0015252lld:lifeskim
pubmed-article:11761085pubmed:issue6lld:pubmed
pubmed-article:11761085pubmed:dateCreated2001-12-11lld:pubmed
pubmed-article:11761085pubmed:abstractTextThe purpose of this study was to compare low-dose (LD) and high-dose (HD) systemic heparinization in a prospective randomized study of arteriovenous carbon dioxide removal (AVCO2R) during acute respiratory distress syndrome, using a commercially available heparin-coated oxygenator. Adult sheep (n = 13) received an LD50 smoke inhalation and 40% TBSA third degree cutaneous flame burn injury. At 40-48 h post-injury, animals underwent cannulation of the carotid artery and jugular vein and were then randomized to HD heparin (activated clotting time, ACT > 300s, n = 6) and LD heparin (ACT < 200s, n =7) and placed on AVCO2R for approximately 72 h using an oxygenator with the Trillium Bio-Passive Surface. Mean ACTs were significantly different, as expected (HD: 446 +/- 26s, LD: 213 +/- 12s, p < 0.05). AVCO2R shunt flow averaged approximately 13% of cardiac output with mean CO2 removal similar in HD and LD, p = NS. The hematocrit, platelet count, and fibrin degradation products for the two groups were not different. No differences in thrombosis or bleeding were noted. In conclusion, LD systemic heparin (ACT < 200s) with a heparin-coated oxygenator does not increase thrombogenicity during AVCO2R for smoke/burn-induced severe lung injury in sheep.lld:pubmed
pubmed-article:11761085pubmed:languageenglld:pubmed
pubmed-article:11761085pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11761085pubmed:citationSubsetIMlld:pubmed
pubmed-article:11761085pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11761085pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11761085pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11761085pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11761085pubmed:statusMEDLINElld:pubmed
pubmed-article:11761085pubmed:monthNovlld:pubmed
pubmed-article:11761085pubmed:issn0267-6591lld:pubmed
pubmed-article:11761085pubmed:authorpubmed-author:MurphyJ AJAlld:pubmed
pubmed-article:11761085pubmed:authorpubmed-author:Zwischenberge...lld:pubmed
pubmed-article:11761085pubmed:authorpubmed-author:DahlH PHPlld:pubmed
pubmed-article:11761085pubmed:authorpubmed-author:SavageC MCMlld:pubmed
pubmed-article:11761085pubmed:authorpubmed-author:AlpardS KSKlld:pubmed
pubmed-article:11761085pubmed:authorpubmed-author:JayroeJ BJBlld:pubmed
pubmed-article:11761085pubmed:issnTypePrintlld:pubmed
pubmed-article:11761085pubmed:volume16lld:pubmed
pubmed-article:11761085pubmed:ownerNLMlld:pubmed
pubmed-article:11761085pubmed:authorsCompleteYlld:pubmed
pubmed-article:11761085pubmed:pagination460-8lld:pubmed
pubmed-article:11761085pubmed:dateRevised2003-11-14lld:pubmed
pubmed-article:11761085pubmed:meshHeadingpubmed-meshheading:11761085...lld:pubmed
pubmed-article:11761085pubmed:meshHeadingpubmed-meshheading:11761085...lld:pubmed
pubmed-article:11761085pubmed:meshHeadingpubmed-meshheading:11761085...lld:pubmed
pubmed-article:11761085pubmed:meshHeadingpubmed-meshheading:11761085...lld:pubmed
pubmed-article:11761085pubmed:meshHeadingpubmed-meshheading:11761085...lld:pubmed
pubmed-article:11761085pubmed:meshHeadingpubmed-meshheading:11761085...lld:pubmed
pubmed-article:11761085pubmed:meshHeadingpubmed-meshheading:11761085...lld:pubmed
pubmed-article:11761085pubmed:meshHeadingpubmed-meshheading:11761085...lld:pubmed
pubmed-article:11761085pubmed:meshHeadingpubmed-meshheading:11761085...lld:pubmed
pubmed-article:11761085pubmed:meshHeadingpubmed-meshheading:11761085...lld:pubmed
pubmed-article:11761085pubmed:meshHeadingpubmed-meshheading:11761085...lld:pubmed
pubmed-article:11761085pubmed:meshHeadingpubmed-meshheading:11761085...lld:pubmed
pubmed-article:11761085pubmed:meshHeadingpubmed-meshheading:11761085...lld:pubmed
pubmed-article:11761085pubmed:meshHeadingpubmed-meshheading:11761085...lld:pubmed
pubmed-article:11761085pubmed:meshHeadingpubmed-meshheading:11761085...lld:pubmed
pubmed-article:11761085pubmed:meshHeadingpubmed-meshheading:11761085...lld:pubmed
pubmed-article:11761085pubmed:meshHeadingpubmed-meshheading:11761085...lld:pubmed
pubmed-article:11761085pubmed:meshHeadingpubmed-meshheading:11761085...lld:pubmed
pubmed-article:11761085pubmed:year2001lld:pubmed
pubmed-article:11761085pubmed:articleTitleLow-dose versus high-dose heparinization during arteriovenous carbon dioxide removal.lld:pubmed
pubmed-article:11761085pubmed:affiliationDepartment of Surgery, The University of Texas Medical Branch, Galveston 77555-0528, USA.lld:pubmed
pubmed-article:11761085pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11761085lld:pubmed